Display Settings:

Format

Send to:

Choose Destination
    Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11479-84. Epub 2006 Jul 24.

    Targeting lentiviral vectors to specific cell types in vivo.

    Source

    Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.

    Abstract

    We have developed an efficient method to target lentivirus-mediated gene transduction to a desired cell type. It involves incorporation of antibody and fusogenic protein as two distinct molecules into the lentiviral surface. The fusogen is constructed by modifying viral envelope proteins, so that they lack the ability to bind to their cognate receptor but still retain the ability to trigger pH-dependent membrane fusion. Thus, the specificity of such a lentiviral vector is solely determined by the antibody, which is chosen to recognize a specific surface antigen of the desired cell type. This specific binding then induces endocytosis of the surface antigen, bringing the lentivirus into an endosome. There, the fusogen responds to the low pH environment and mediates membrane fusion, allowing the virus core to enter the cytosol. Using CD20 as a target antigen for human B cells, we have demonstrated that this targeting strategy is effective both in vitro and in intact animals. This methodology is flexible and can be extended to other forms of cell type-specific recognition to mediate targeting. The only requirement is that the antibody (or other binding protein) must be endocytosed after interaction with its cell surface-binding determinant.

    PMID:
    16864770
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC1518805
    Free PMC Article

    Images from this publication.See all images (4) Free text

    Fig. 1.
    Fig. 3.
    Fig. 2.
    Fig. 4.

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central Icon for F1000

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk